Drugs / SA3Ag
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01643941 | Aug 2012 → May 2013 | staphylococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01018641 | Jan 2010 → Jan 2011 | staphylococcal toxemia | Pfizer | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-05-09 | Pfizer | Results Staphylococcus aureus Investigational Vaccine Elicits a Positive Immune Response in Phase 1 Study pfizer.com ↗
In the Phase 1 study, the vaccine elicited a positive immune response to each of the three components. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-05-09 | Pfizer | Staphylococcus aureus Investigational Vaccine Elicits a Positive Immune Response in Phase 1 Study pfizer.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SA3Ag | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01643941 ↗ |
| Modality | Vaccine | “a prophylactic vaccine is being developed that may reduce this disease burden.” PMID 25707693 ↗ Feb 2015 |
| Route | Intramuscular | “In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1.” NCT01018641 ↗ |